Literature DB >> 27292188

ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.

Maria Anna Zipeto1, Angela C Court1, Anil Sadarangani1, Nathaniel P Delos Santos1, Larisa Balaian1, Hye-Jung Chun2, Gabriel Pineda1, Sheldon R Morris1, Cayla N Mason1, Ifat Geron1, Christian Barrett3, Daniel J Goff1, Russell Wall1, Maurizio Pellecchia4, Mark Minden5, Kelly A Frazer3, Marco A Marra2, Leslie A Crews1, Qingfei Jiang6, Catriona H M Jamieson7.   

Abstract

Post-transcriptional adenosine-to-inosine RNA editing mediated by adenosine deaminase acting on RNA1 (ADAR1) promotes cancer progression and therapeutic resistance. However, ADAR1 editase-dependent mechanisms governing leukemia stem cell (LSC) generation have not been elucidated. In blast crisis chronic myeloid leukemia (BC CML), we show that increased JAK2 signaling and BCR-ABL1 amplification activate ADAR1. In a humanized BC CML mouse model, combined JAK2 and BCR-ABL1 inhibition prevents LSC self-renewal commensurate with ADAR1 downregulation. Lentiviral ADAR1 wild-type, but not an editing-defective ADAR1(E912A) mutant, induces self-renewal gene expression and impairs biogenesis of stem cell regulatory let-7 microRNAs. Combined RNA sequencing, qRT-PCR, CLIP-ADAR1, and pri-let-7 mutagenesis data suggest that ADAR1 promotes LSC generation via let-7 pri-microRNA editing and LIN28B upregulation. A small-molecule tool compound antagonizes ADAR1's effect on LSC self-renewal in stromal co-cultures and restores let-7 biogenesis. Thus, ADAR1 activation represents a unique therapeutic vulnerability in LSCs with active JAK2 signaling.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27292188      PMCID: PMC4975616          DOI: 10.1016/j.stem.2016.05.004

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  65 in total

1.  Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells.

Authors:  Ryan D Morin; Michael D O'Connor; Malachi Griffith; Florian Kuchenbauer; Allen Delaney; Anna-Liisa Prabhu; Yongjun Zhao; Helen McDonald; Thomas Zeng; Martin Hirst; Connie J Eaves; Marco A Marra
Journal:  Genome Res       Date:  2008-02-19       Impact factor: 9.043

Review 2.  Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Caterina de Benedittis; Manuela Mancini; Giovanni Martinelli
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

3.  Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms.

Authors:  Elena Piskounova; Christos Polytarchou; James E Thornton; Robert J LaPierre; Charalabos Pothoulakis; John P Hagan; Dimitrios Iliopoulos; Richard I Gregory
Journal:  Cell       Date:  2011-11-23       Impact factor: 41.582

4.  DARNED: a DAtabase of RNa EDiting in humans.

Authors:  Anmol Kiran; Pavel V Baranov
Journal:  Bioinformatics       Date:  2010-06-14       Impact factor: 6.937

Review 5.  Functions and regulation of RNA editing by ADAR deaminases.

Authors:  Kazuko Nishikura
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

Review 6.  RNA editome imbalance in hepatocellular carcinoma.

Authors:  Lihua Qi; Tim Hon Man Chan; Daniel G Tenen; Leilei Chen
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

7.  Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR).

Authors:  Oz Solomon; Shirley Oren; Michal Safran; Naamit Deshet-Unger; Pinchas Akiva; Jasmine Jacob-Hirsch; Karen Cesarkas; Reut Kabesa; Ninette Amariglio; Ron Unger; Gideon Rechavi; Eran Eyal
Journal:  RNA       Date:  2013-03-08       Impact factor: 4.942

8.  Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways.

Authors:  Jae Hoon Bahn; Jaegyoon Ahn; Xianzhi Lin; Qing Zhang; Jae-Hyung Lee; Mete Civelek; Xinshu Xiao
Journal:  Nat Commun       Date:  2015-03-09       Impact factor: 14.919

9.  Profiling RNA editing in human tissues: towards the inosinome Atlas.

Authors:  Ernesto Picardi; Caterina Manzari; Francesca Mastropasqua; Italia Aiello; Anna Maria D'Erchia; Graziano Pesole
Journal:  Sci Rep       Date:  2015-10-09       Impact factor: 4.379

10.  Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.

Authors:  Aparna Raval; Stephan M Tanner; John C Byrd; Elizabeth B Angerman; James D Perko; Shih-Shih Chen; Björn Hackanson; Michael R Grever; David M Lucas; Jennifer J Matkovic; Thomas S Lin; Thomas J Kipps; Fiona Murray; Dennis Weisenburger; Warren Sanger; Jane Lynch; Patrice Watson; Mary Jansen; Yuko Yoshinaga; Richard Rosenquist; Pieter J de Jong; Penny Coggill; Stephan Beck; Henry Lynch; Albert de la Chapelle; Christoph Plass
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

View more
  88 in total

1.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

2.  RNA editing as an activator of self-renewal in cancer.

Authors:  Igal Germanguz; William E Lowry
Journal:  Stem Cell Investig       Date:  2016-10-31

Review 3.  ADAR RNA editing in human disease; more to it than meets the I.

Authors:  Angela Gallo; Dragana Vukic; David Michalík; Mary A O'Connell; Liam P Keegan
Journal:  Hum Genet       Date:  2017-09-14       Impact factor: 4.132

Review 4.  The role of A-to-I RNA editing in cancer development.

Authors:  Xiaoyan Xu; Yumeng Wang; Han Liang
Journal:  Curr Opin Genet Dev       Date:  2017-11-08       Impact factor: 5.578

Review 5.  Non-coding RNA networks in cancer.

Authors:  Eleni Anastasiadou; Leni S Jacob; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2017-11-24       Impact factor: 60.716

Review 6.  When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference.

Authors:  Yumeng Wang; Han Liang
Journal:  Bioessays       Date:  2017-12-27       Impact factor: 4.345

Review 7.  ADARs, RNA editing and more in hematological malignancies.

Authors:  Phaik Ju Teoh; Mun Yee Koh; Wee Joo Chng
Journal:  Leukemia       Date:  2020-11-02       Impact factor: 11.528

8.  LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model.

Authors:  Lydia Meder; Katharina König; Felix Dietlein; Iris Macheleidt; Alexandra Florin; Meryem S Ercanoglu; Ursula Rommerscheidt-Fuss; Mirjam Koker; Gisela Schön; Margarete Odenthal; Florian Klein; Reinhard Büttner; Johannes H Schulte; Lukas C Heukamp; Roland T Ullrich
Journal:  Oncogene       Date:  2018-03-05       Impact factor: 9.867

9.  Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation.

Authors:  Qingfei Jiang; Jane Isquith; Maria Anna Zipeto; Raymond H Diep; Jessica Pham; Nathan Delos Santos; Eduardo Reynoso; Julisia Chau; Heather Leu; Elisa Lazzari; Etienne Melese; Wenxue Ma; Rongxin Fang; Mark Minden; Sheldon Morris; Bing Ren; Gabriel Pineda; Frida Holm; Catriona Jamieson
Journal:  Cancer Cell       Date:  2019-01-03       Impact factor: 31.743

10.  RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML.

Authors:  Leslie A Crews; Larisa Balaian; Nathaniel P Delos Santos; Heather S Leu; Angela C Court; Elisa Lazzari; Anil Sadarangani; Maria A Zipeto; James J La Clair; Reymundo Villa; Anna Kulidjian; Rainer Storb; Sheldon R Morris; Edward D Ball; Michael D Burkart; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2016-08-25       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.